Oncolytic Virus Therapies Market Report by Virus Type (Genetically Engineered Oncolytic Viruses, Oncolytic Wild-Type Viruses), Application (Solid Tumors, Melanoma), End Use (Hospitals, Specialty Clinics, Cancer Research Institute), and Region 2026-2034

Oncolytic Virus Therapies Market Report by Virus Type (Genetically Engineered Oncolytic Viruses, Oncolytic Wild-Type Viruses), Application (Solid Tumors, Melanoma), End Use (Hospitals, Specialty Clinics, Cancer Research Institute), and Region 2026-2034

Report Format: PDF+Excel | Report ID: SR112026A6592

Market Overview:

The global oncolytic virus therapies market size reached USD 222.0 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 815.4 Million by 2034, exhibiting a growth rate (CAGR) of 15.09% during 2026-2034.

Report Attribute 
Key Statistics
Base Year
2025
Forecast Years
2026-2034
Historical Years
2020-2025
Market Size in 2025
USD 222.0 Million
Market Forecast in 2034
USD 815.4 Million
Market Growth Rate 2026-2034 15.09%

Oncolytic virus therapies are a form of immunotherapy that utilizes viruses to infect and destroy cancer cells. They use various natural and genetically modified viruses, such as herpes simplex, Newcastle disease, vaccinia, adenovirus, reovirus, and picornavirus. Oncolytic virus therapies activate danger signals for generating an immune response and are widely used for treating solid tumors, melanoma, and unresectable lesions. They also help eradicate tumors using viruses that only infect and destroy targeted tumor cells. As compared to chemotherapy, oncolytic virus therapies are non-toxic, provide superior efficacy, and prolong the survival of cancer patients. As a result, they find extensive applications in hospitals, clinics, and cancer research institutes.

Oncolytic Virus Therapies Market Size

To get more information on this market Request Sample

Oncolytic Virus Therapies Market Trends:

The rising incidences of cancer across the globe are creating a positive outlook for the market. Oncolytic virus therapies are widely used to treat various cancers, such as glioblastoma, breast, lung, and prostate cancers, due to their powerful anti-tumor properties and ability to target tumors accurately without harming surrounding tissues. In line with this, the widespread utilization of the therapy to treat various types of melanomas, such as hematological malignancies, lymphoma, leukemia, and myeloma, is favoring the market growth. Furthermore, rising concerns among patients regarding the negative health impact of various cancer treatments, such as surgical intervention, radiotherapy, chemotherapy, and immunotherapy, are providing a considerable boost to the market growth. Additionally, the rising number of clinical studies in oncolytic viruses, such as herpesvirus, adenovirus, and vaccinia virus, that is in the final stages and have demonstrated excellent experimental results are facilitating the market growth. Other factors, including rising demand for advanced treatments and novel therapies and increasing initiatives by several governments to spread awareness regarding different causes of cancer and promote early diagnosis, are anticipated to drive the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global oncolytic virus therapies market report, along with forecasts at the global, regional and country level from 2026-2034. Our report has categorized the market based on virus type, application and end use.

Breakup by Virus Type:

  • Genetically Engineered Oncolytic Viruses
    • Herpes Simplex Virus
    • Adenovirus
    • Vaccinia Virus
  • Oncolytic Wild-Type Viruses
    • Reovirus
    • Newcastle Disease Virus
    • Vesicular Stomatitis Virus
       

Breakup by Application:

Oncolytic Virus Therapies Market By Application

Access the comprehensive market breakdown Request Sample

  • Solid Tumors
    • Breast Cancer
    • Prostate Cancer
    • Lung Cancer
    • Glioblastoma
  • Melanoma
    • Hematological Malignancies
    • Lymphoma
    • Leukemia
    • Myeloma
       

Breakup by End Use:

  • Hospitals
  • Specialty Clinics
  • Cancer Research Institute
     

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
     

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Dnatrix Inc., Genelux Corporation, Lokon Pharma AB, Replimune Group Inc., Rigvir Ltd., Sorrento Therapeutics, Takara Bio Inc. (Takara Holdings Inc.), Targovax, TILT Biotherapeutics Ltd, Transgene SA and Vyriad. Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

Report Coverage:

Report Features Details
Base Year of the Analysis 2025
Historical Period 2020-2025
Forecast Period 2026-2034
Units Million USD
Segment Coverage Virus Type, Application, End Use, Region
Region Covered Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Amgen Inc., Dnatrix Inc., Genelux Corporation, Lokon Pharma AB, Replimune Group Inc., Rigvir Ltd., Sorrento Therapeutics, Takara Bio Inc. (Takara Holdings Inc.), Targovax, TILT Biotherapeutics Ltd, Transgene SA and Vyriad.
Customization Scope 10% Free Customization
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


Key Benefits for Stakeholders:

  • IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the oncolytic virus therapies market from 2020-2034.
  • The research study provides the latest information on the market drivers, challenges, and opportunities in the global oncolytic virus therapies market.
  • The study maps the leading as well as the fastest growing regional markets. It further enables stakeholders to identify the key country-level markets within each region.
  • Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the oncolytic virus therapies industry and its attractiveness.
  • Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.

Key Questions Answered in This Report

The global oncolytic virus therapies market was valued at USD 222.0 Million in 2025.

We expect the global oncolytic virus therapies market to exhibit a CAGR of 15.09% during 2026-2034.

The rising demand for oncolytic virus therapies over chemotherapy, as they are non-toxic, provide superior efficacy, prolong the survival of cancer patients, etc., is primarily driving the global oncolytic virus therapies market.

The sudden outbreak of the COVID-19 pandemic had led to the postponement of elective cancer and melanomas therapies to reduce the risk of coronavirus infection upon hospital visits or interaction with healthcare professionals, thereby negatively impacting the global market for oncolytic virus therapies.

On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.

Some of the major players in the global oncolytic virus therapies market include Amgen Inc., Dnatrix Inc., Genelux Corporation, Lokon Pharma AB, Replimune Group Inc., Rigvir Ltd., Sorrento Therapeutics, Takara Bio Inc. (Takara Holdings Inc.), Targovax, TILT Biotherapeutics Ltd, Transgene SA, and Vyriad.

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Oncolytic Virus Therapies Market Report by Virus Type (Genetically Engineered Oncolytic Viruses, Oncolytic Wild-Type Viruses), Application (Solid Tumors, Melanoma), End Use (Hospitals, Specialty Clinics, Cancer Research Institute), and Region 2026-2034
Purchase Options Discount
Offer
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-201-971-6302

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials